Efficacy and Safety of Adalimumab Biosimilar GP2017 in Patients with Inflammatory Bowel Disease

(1) Background: GP2017 is one of the biosimilar drugs of adalimumab, one of the anti-TNF agents used for inflammatory bowel disease (IBD). To date, there is little real-world data about the use of GP2017 in IBD patients. The aim of our study was to evaluate the effectiveness and safety of this biosi...

Descripción completa

Detalles Bibliográficos
Autores principales: Vernero, Marta, Bezzio, Cristina, Ribaldone, Davide G., Costa, Stefania, Scalvini, Davide, Tribocco, Elisa, Manes, Gianpiero, Saibeni, Simone
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10647534/
https://www.ncbi.nlm.nih.gov/pubmed/37959304
http://dx.doi.org/10.3390/jcm12216839

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10647534/
https://www.ncbi.nlm.nih.gov/pubmed/37959304
http://dx.doi.org/10.3390/jcm12216839

Ejemplares similares